Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells

Clinical and Experimental Metastasis

Volumn 23, Issue 1, 2006, Pages 75-86

  Muir, Caroline ^a   Chung, Leland W K ^b   Carson, Daniel D ^a   Farach Carson, Mary C ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Endothelial cells; Heparin binding growth factors; Hypoxia; Prostate cancer; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIGEL; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL ACTIVATION; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; STROMA CELL;

BONE MARROW CELLS; BONE NEOPLASMS; CELL DIVISION; CELL HYPOXIA; CELL LINE, TUMOR; DNA PRIMERS; ENDOTHELIAL CELLS; HUMANS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750074755     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-006-9021-2     Document Type: Article

References (56)

1. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ (2003) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97:739-747
2. Sikes RA, Nicholson BE, Koeneman KS, Edlund NM, Bissonette EA, Bradley MJ, Thalmann GN, Cecchini MG, Pienta KJ, Chung LW (2004) Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer 110:497-503
3. Lehr JE, Pienta KJ (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90:118-123
4. Edlund M (2004) Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem 91:686-705
5. Chung LW (2003) Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 97:772-778
6. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA (2004) Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res 94:316-323
7. Forsten-Williams K, Chua CC, Nugent MA (2005) The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J Theor Biol 233:483-499
8. Farach-Carson MC, Hecht JT, Carson DD (2005) Heparan sulfate proteoglycans: key players in cartilage biology. Crit Rev Eukaryot Gene Expr 15:29-48
9. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, Tosatti MP, Presta M (2003) Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 162:1913-1926
10. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-178
11. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, Fang L, Lee SW (2004) HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64:5283-5290
12. Sanderson RD, Yang Y, Suva LJ, Kelly T (2004) Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 23:341-352
13. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
14. Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11:293-299
15. Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14:1983-1991
16. Brahimi-Horn C, Berra E, Pouyssegur J (2001) Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 11:S32-S36
17. 2 tension. Am J Physiol 271:C1172-C1180
18. Brahimi-Horn C, Mazure N, Pouyssegur J (2005) Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 17:1-9
19. Brahimi-Horn C, Pouyssegur J (2005) When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy. Crit Rev Oncol Hematol 53:115-123
20. Srinivas V, Zhang LP, Zhu XH, Caro J (1999) Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun 260:557-561
21. Sang N, Fang J, Srinivas V, Leshchinsky I, Caro J (2002) Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22:2984-2992
22. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466-1471
23. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861
24. Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26:25-35
25. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613
26. Lee TH, Avraham HK, Jiang S, Avraham S (2003) Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 278:5277-5284
27. Zheng L, Roeder RG, Luo Y (2003) S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 114(2):255-266
28. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z Keller ET (2005) Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 65(23):10921-10929
29. Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW, Kim YJ (2001) Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res 61:3290-3293
30. Savorè C, Zhang C, Muir C, Liu R, Wyrwa J, Shu J, Zhau HE, Chung LWK, Carson DD, Farach-Carson MC (2005) Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 22:377-390
31. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C (2002) Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 291:908-914
32. Zhong H, Semenza GL, Simons JW, De Marzo AM (2004) Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 28:88-93
33. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW (2003) Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9:2416-2425
34. Ghafar MA, Anastasiadis AG, Chen MW, Burchardt M, Olsson LE, Xie H, Benson MC, Buttyan R (2003) Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 54:58-67
35. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, Klocker H (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57:57-65
36. Chavakis E, Dimmeler S (2002) Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 22:887-893
37. Hrouda D, Nicol DL, Gardiner RA (2003) The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 30:347-355
38. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572
39. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD (2002) A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62:854-859
40. Qi L, Robinson WA, Brady BM, Glode LM (2003) Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 23:3917-3922
41. Chen J, De S, Brainard J, Byzova TV (2004) Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes 11:1-11
42. Claesson-Welsh L (2003) Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 31:20-24
43. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995
44. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF (1998) Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 273:29979-29985
45. Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272:23659-23667
46. Lee SJ, Lee HM, Ji ST, Lee SR, Mar W, Gho YS (2004) 1,2,3,4,6-Penta-O- galloyl-beta-D-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor. Cancer Lett 208:89-94
47. Kou B, Li Y, Zhang L, Zhu G, Wang X, Xia J, Shi Y (2004) In vivo inhibition of tumor angiogenesis by a soluble VEG-FR-2 fragment. Exp Mol Pathol 76:129-137
48. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL (2005) The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11:7658-7663
49. Zhau HE, Li CL, Chung LW (2000) Establishment of human prostate carcinoma skeletal metastasis models. Cancer 88:2995-3001
50. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581
51. Roecklein BA, Torok-Storb B (1995) Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85:997-1005
52. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23
53. Van Lieshout T, Stanisz J, Espiritu V, Richardson M, Singh G (2003)Ahypoxic response induced in MatLyLu cells by cobalt chloride results in an enhanced angiogenic response by the chick chorioallantoic membrane. Int J Oncol 23:745-750
54. Nakayama K, Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K, Fukumoto M, Takebayashi Y (2002) Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 176:215-223
55. Gomm JJ, Browne PJ, Coope RC, Bansal GS, Yiangou C, Johnston CL, Mason R, Coombes RC (1997) A paracrine role for myoepithelial cell-derived FGF2 in the normal human breast. Exp Cell Res 234:165-173
56. Meister B, Grunebach F, Bautz F, Brugger W, Fink FM, Kanz L, Mohle R (1999) Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer 35:445-449